DI GIACOMO ANNA MARIA

Teaching activities

Completion accademic year: 2024/2025

Course year: 2 First cycle degree (DM 270) DIETISTIC A.Y. 2023/2024
Course year: 1 Second cycle degree (Laurea Magistrale) MEDICAL BIOTECHNOLOGIES A.Y. 2024/2025
Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2019/2020

Completion accademic year: 2023/2024

Course year: 2 First cycle degree (DM 270) DIETISTIC A.Y. 2022/2023
Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2018/2019

Completion accademic year: 2022/2023

Course year: 2 First cycle degree (DM 270) DIETISTIC A.Y. 2021/2022
Course year: 6 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2017/2018

Completion accademic year: 2021/2022

Course year: 2 ONCOLOGIA MEDICA A.Y. 2020/2021
Course year: 1 CHIRURGIA GENERALE A.Y. 2021/2022
Course year: 3 ONCOLOGIA MEDICA A.Y. 2019/2020

Research

Ultime pubblicazioni:

  • Di Giacomo, A.M., Lahn, M., Eggermont, A.M., Fox, B., Ibrahim, R., Sharma, P., et al. (2024). The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?. EUROPEAN JOURNAL OF CANCER, 198 [10.1016/j.ejca.2023.113501]. - view more
  • Simonetti, E., Cutarella, S., Valente, M., Sani, T., Ravara, M., Maio, M., et al. (2023). From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma. ONCOTARGETS AND THERAPY, 16, 227-232 [10.2147/OTT.S368408]. - view more
  • Cusi, M.G., Di Giacomo, A.M., Anichini, G., Gori Savellini, G., Terrosi, C., Gandolfo, C., et al. (2023). Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID. VIRUSES, 15(3), 614 [10.3390/v15030614]. - view more
  • Cantini, L., Paoloni, F., Pecci, F., Spagnolo, F., Genova, C., Tanda, E.T., et al. (2023). Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 115(7), 796-804 [10.1093/jnci/djad061]. - view more
  • Omuro, A., Brandes, A.A., Carpentier, A.F., Idbaih, A., Reardon, D.A., Cloughesy, T., et al. (2023). Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. NEURO-ONCOLOGY, 25(1), 123-134 [10.1093/neuonc/noac099]. - view more